Immune Response Corporation and Orchestra Therapeutics, Inc.

The Immune Response Corporation announced on April 16, 2007 that it was changing its name to Orchestra Therapeutics, Inc. The company annunced the rebranding as an effort to reflect expanded focus on Treatment of Autoimmune Disease. The company also annouced that it was terminating its HIV clinical trials to focus fully on its autoimmune program. The company's lead immune-based therapeutic product candidate is NeuroVax(TM) for the treatment of MS.